News

Boston Scientific (BSX) reported Q2 revenue and EPS that beat expectations but lowered its full-year

BSX faces WATCHMAN and EP pressures as management cuts outlook while highlighting cost savings and new product catalysts for future growth.

Moby summary of Boston Scientific Corporation's Q2 2026 earnings call

Boston Scientific (NYSE:BSX) reported second-quarter 2026 revenue growth at the high end of its guidance range and adjusted earnings per share above expectations, but lowered its full-year outlook as it faces slowing demand in its WATCHMAN left atrial appendage closure business and increased competi

Boston Scientific Corp (BSX) reports a robust Q2 with 7% organic sales growth and a 15% increase in adjusted EPS, despite challenges in some segments.

The medical device maker topped second-quarter expectations but now sees full-year adjusted EPS of $3.28 to $3.32, down from a prior range of $3.34 to $3.41

The main US stock measures were mostly trending higher in Wednesday's premarket activity as traders

July 29 (Reuters) - Medical device maker Boston Scientific on Wednesday lowered its annual profit forecast, citing pressure on its Watchman heart device business.

Wall Street analysts are busy reshuffling their ratings ahead of the Fed meeting, with surprise double-upgrades, dramatic target cuts, and fresh initiations spanning surgical robots to cybersecurity. Find out which names made the biggest moves today.

Medical device company Boston Scientific (NYSE:BSX) will be reporting earnings this Wednesday morning. Here’s what to expect.

The trade tech company says Cervo AI can speed up customs brokerage tasks as tariff and trade policies shift.

Boston Scientific is gearing up for earnings day, weighing a rocky stock run against Wall Street's stubbornly optimistic outlook.

Sometimes boring stocks can be the most exciting.

TFX targets $2.03B in divestiture proceeds; FTC review, tariffs and remediation costs put 2026 timing, margins and leverage in play.

Boston Scientific (BSX) shares fell Wednesday after Chief Executive Mike Mahoney's comments about fl

Boston Scientific's CEO stated that the company will update its three-year plan, including targets for FY27 and FY28, after the third-quarter earnings call.

(Bloomberg) -- For years, there was only one way for mom-and-pop investors to buy into Elon Musk’s vision: shares of Tesla Inc. That’s about to change — and it’s a serious risk for Tesla investors. Most Read from BloombergStocks Fall, Oil Rises as Hormuz Deal Hopes Fade: Markets WrapBillionaire Rinehart Bets $100 Million on US Defense StocksIranian Media Said US Offered Interim Waiver on Oil SanctionsUS and Iran Far From Deal as Bond Rout Piles Pressure on TrumpWinners and Losers From Trump and

Moby summary of Elutia Inc.'s Q1 2026 earnings call